Pfizer vaccine on track for regulatory review in October

 From Bloomberg:

Pfizer Inc. and BioNTech SE said the Covid-19 vaccine they are jointly developing is on track to be submitted for regulatory review as early as October, as they released additional data from an early-stage study.

The companies said the vaccine was well tolerated with mild to moderate fever in fewer than 20% of the participants. The companies are continuing to analyze data from the Phase 1 trials in the U.S. and Germany, they said in a statement.

The timeline would make the vaccine one of the fastest-moving in the world. Some analysts expect a vaccine to be approved for use by November in the U.S., a move which may give President Donald Trump a new foothold in the election.

If any of the vaccines now being tested works, and is released for use over the next few months, the world can go back to "normal" in 2021.  But don't expect world GDP to reach the pre-covid high until end 2022.  If governments choose austerity to try and get debts down, it won't happen even then.